ONCT - Oncternal Therapeutics Inc Stock Price, Fair Value and News

$0.530.00 (0.00%)

Market Closed as of 02 Jan 2025, 04:00 pm ET

ONCT Stock Valuation Analysis

Valuation

Max Portfolio %

ONCT Price Action

ONCT RSI Chart

ONCT Stock Valuation Analysis

Valuation

Max Portfolio %

ONCT Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ONCT Fundamentals

ONCT Revenue

ONCT Earnings

ONCT Profitability

ONCT Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.2M	1.8M	2.2M	-
2023	947.0K	862.0K	659.0K	785.0K
2022	4.3M	3.6M	1.9M	1.5M
2021	3.5M	3.8M	5.3M	4.3M
2020	2.5M	2.5M	2.5M	3.4M
2019	2.8M	1.9M	2.2M	2.4M
2018	-	5.0M	5.3M	4.0M
2012	5.5M	5.5M	-	-
2011	45.5M	34.3M	23.0M	11.7M
2010	-	28.7M	42.8M	56.8M
2009	-	-	-	14.7M

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

CEO	Dr. James B. Breitmeyer M.D., Ph.D.
WEBSITE	oncternal.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	30